Molecular Testing as Triage in Cervical Cancer Screening: Economic Evaluation Using Headroom Analysis
Cancers,
Journal Year:
2025,
Volume and Issue:
17(4), P. 612 - 612
Published: Feb. 11, 2025
Background:
Molecular
triage
testing
for
high-risk
human
papillomavirus
(hrHPV)-based
cervical
cancer
screening
can
be
used
in
self-sampling,
potentially
reducing
unnecessary
colposcopies
and
increasing
attendance.
However,
its
commercial
value
remains
underexplored.
This
study
headroom
analysis
to
estimate
the
maximum
reimbursable
price
(MRP)
at
which
molecular
would
cost-effective
of
hrHPV-positive
women,
compared
with
cytology.
Methods:
A
validated
microsimulation
Markov
model
Dutch
program
evaluated
three
scenarios:
(1)
cytology
(base
scenario),
(2)
self-samples
only
(scenario
I),
(3)
on
self-
GP-collected
samples
II).
Test
sensitivity
specificity
ranged
from
65%
95%,
a
threshold
EUR
20,000
per
life-year
gained.
Results:
In
scenario
I,
MRPs
244
(85%
sensitivity,
75%
specificity)
435
(95%
95%
specificity).
II,
was
across
all
parameters,
162
(65%
624
Increasing
did
not
significantly
affect
life-years
gained
(due
low
mortality
Netherlands),
but
increased
reduce
number
colposcopies.
Conclusions:
Enhancing
will
improve
by
colposcopy
referrals
without
affecting
Language: Английский
Meta-analysis of the diagnostic value of SOX1 methylation in different types of cervical cancer
World Journal of Surgical Oncology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: April 21, 2025
This
meta-analysis
evaluates
the
diagnostic
value
of
SOX1
methylation
across
different
cervical
cancer
types,
including
squamous
cell
carcinoma
and
adenocarcinoma,
to
assess
its
efficacy
as
a
biomarker.
We
reviewed
studies
published
up
March
2024,
employing
PICOS-based
search
strategy
in
databases
like
PubMed
Web
Science.
included
clinical
providing
performance
indicators
while
excluding
non-clinical
small-sample
studies.
Meta-Disc1.4
Stata15.1
were
used
for
statistical
analyses
focusing
on
methylation's
sensitivity,
specificity,
odds
ratio.
Twelve
articles
encompassing
18
with
3,213
subjects
analyzed.
The
overall
DOR
diagnosis
was
68.95
(95%CI:
27.63-172.07),
Summary
Receiver
Operating
Characteristic
AUC
0.92,
indicating
high
accuracy.
Specifically,
adenocarcinoma
87.57
7.05-1087.44)
an
0.89,
carcinoma,
it
245.87
(95%
CI:
26.49-2282.40)
0.93,
reflecting
significant
potential
both
types.
No
substantial
publication
bias
detected
(P
>
0.10).
gene
demonstrates
cervix,
particularly
effective
large
sample
sizes
exfoliated
samples
early
detection
screening,
supporting
utility
reliable
Language: Английский